Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.
Latest update： 30/11/2016 17:37:49
Amine Pharma Research Institute Co., Ltd.
We offer cerebral infarction risk assessment for detecting the risk of cerebral infarction just using blood.
We are developing a cerebral infarction risk assessment service that detects cerebral infarction using a simple blood test. It can be utilized as a first screening for imaging examinations, such as medical checkups of the brain. The risk of cerebral infarction (asymptomatic cerebral infarction) can be detected with about 85% accuracy by measuring three items: the cell injury marker acrolein, the inflammatory marker IL-6, and CRP.
[Company strength] We are developing a world-leading cerebral infarction risk assessment service. Our service contributes to health maintenance during the pre-symptomatic stage before a person is struck by a cerebral infarction, and it is now widely utilized. One of the strengths of our system is to take basic research in biochemistry and elevate it into the application stage with the use of industry-academia cooperation. We can cooperate with your company in basic biochemical research on the physiologically active substance polyamine, and in research on the clinical application of polyamine-related substances, etc. [Business description] We are developing our business by delivering our cerebral infarction risk assessment method. This is an easy, low-cost method for detecting the risk of cerebral infarction just using blood. We have delivered it to more than 200 medical organizations, multiple private health insurance societies, and mutual aid societies nationwide. [Industry] Services associated with medical treatment and R&D of diagnostic agents [Strength of products/technologies] Our cerebral infarction risk assessment can detect the risk of cerebral infarction at a low cost just using blood. It can be utilized as a first screening in imaging examinations such as medical checkups of the brain. It can detect the risk of cerebral infarction (asymptomatic cerebral infarction) with about 85% accuracy by measuring three items: the cell injury marker acrolein, the inflammatory marker IL-6, and CRP. [Representative's message] Our company was founded as a Chiba University venture in 2007. Our goals are to reduce the number of patients who suffer from cerebral infarction, and to have university-originated technology utilized in society. One of our strong points is in the research stage for developing applications of the high-level basic research in the university, etc. We also plan to use cerebral infarction risk assessment to contribute to reducing medical expenses in society. Please feel free to contact us if you are planning to introduce cerebral infarction risk assessment or if you share our philosophy and wish to conduct joint R&D with us. [Company structure for market development/overseas expansion] Our company is a small organization, but our R&D and management planning teams will unite to provide you with sincere support. [Awards and media coverage] [Awards] Venture Cup Chiba Grand Prize (2007); 23rd SME Excellent New Technology and New Product Award (2011); Award of Shining Industrial Technology in 9 Prefectures and Cities, 2011. [Media] Nikkei Business, “100 next-generation ventures that save the world” (October 8, 2012); Medical Science Direct, November Special Issue (November 30, 2013); TBS, “Hanamaru Market” (April 9, 2013); Nippon TV, “Shuichi” (September 29, 2013). [Joint research and development] New Energy and Industrial Technology Development Organization (consignment research); Chiba University (National University Corporation) (joint research); Kake Educational Institute, Chiba Institute of Science (joint research). [Main Clients / Business History (domestic)] More than 200 organizations such as private health insurance societies (accepted as an item covered by health insurance), municipal mutual aid societies (accepted as a covered item), medical examination centers, and medical institutions (accepted as an option for complete physical examinations). [Exhibition History/Information] Tokyo International Industry Exhibition 2012. Innovation Japan 2014.
This company is recommended by the following support organizations.
- Kanto Head Office, SMRJ